120 related articles for article (PubMed ID: 1695996)
1. Monoclonal antibody-dependent, cell-mediated cytotoxicity against human malignant gliomas.
Takahashi H; Belser PH; Atkinson BF; Sela BA; Ross AH; Biegel J; Emanuel B; Sutton L; Koprowski H; Herlyn D
Neurosurgery; 1990 Jul; 27(1):97-102. PubMed ID: 1695996
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibodies with cytotoxic reactivities against human gliomas.
Nanda A; Liwnicz B; Atkinson BF; Sela BA; Takahashi H; Belser PH; Black P; Koprowski H; Herlyn D
J Neurosurg; 1989 Dec; 71(6):892-7. PubMed ID: 2585082
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies in neuro-oncology.
Stavrou D
Neurosurg Rev; 1990; 13(1):7-18. PubMed ID: 2181345
[TBL] [Abstract][Full Text] [Related]
4. Production and characterization of two human glioma xenograft-localizing monoclonal antibodies.
Wikstrand CJ; McLendon RE; Bullard DE; Fredman P; Svennerholm L; Bigner DD
Cancer Res; 1986 Nov; 46(11):5933-40. PubMed ID: 3756930
[TBL] [Abstract][Full Text] [Related]
5. Antigen related to cell proliferation in malignant gliomas recognized by a human monoclonal antibody.
Kokunai T; Tamaki N; Matsumoto S
J Neurosurg; 1990 Dec; 73(6):901-8. PubMed ID: 2230972
[TBL] [Abstract][Full Text] [Related]
6. Enhanced cytotoxicity against colon carcinoma by combinations of noncompeting monoclonal antibodies to the 17-1A antigen.
Fogler WE; Klinger MR; Abraham KG; Gottlinger HG; Riethmuller G; Daddona PE
Cancer Res; 1988 Nov; 48(22):6303-8. PubMed ID: 2460221
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies against epitopes on ganglioside GD2 and its lactones. Markers for gliomas and neuroblastomas.
Bosslet K; Mennel HD; Rodden F; Bauer BL; Wagner F; Altmannsberger A; Sedlacek HH; Wiegandt H
Cancer Immunol Immunother; 1989; 29(3):171-8. PubMed ID: 2471592
[TBL] [Abstract][Full Text] [Related]
8. Both the epitope specificity and isotype are important in the antitumor effect of monoclonal antibodies against Her-2/neu antigen.
Kim KM; Shin EY; Moon JH; Heo TH; Lee JY; Chung Y; Lee YJ; Cho HM; Shin SU; Kang CY
Int J Cancer; 2002 Dec; 102(4):428-34. PubMed ID: 12402315
[TBL] [Abstract][Full Text] [Related]
9. Phenotyping of 60 cultured human gliomas and 34 other neuroectodermal tumors by means of monoclonal antibodies against glioma, melanoma and HLA-DR antigens.
de Muralt B; de Tribolet N; Diserens AC; Stavrou D; Mach JP; Carrel S
Eur J Cancer Clin Oncol; 1985 Feb; 21(2):207-16. PubMed ID: 2985398
[TBL] [Abstract][Full Text] [Related]
10. Emerging monoclonal antibody therapies for malignant gliomas.
Gerber DE; Laterra J
Expert Opin Investig Drugs; 2007 Apr; 16(4):477-94. PubMed ID: 17371196
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas.
Wikstrand CJ; Hale LP; Batra SK; Hill ML; Humphrey PA; Kurpad SN; McLendon RE; Moscatello D; Pegram CN; Reist CJ
Cancer Res; 1995 Jul; 55(14):3140-8. PubMed ID: 7606735
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy of human glioma xenografts with unlabeled, 131I-, or 125I-labeled monoclonal antibody 425 to epidermal growth factor receptor.
Bender H; Takahashi H; Adachi K; Belser P; Liang SH; Prewett M; Schrappe M; Sutter A; Rodeck U; Herlyn D
Cancer Res; 1992 Jan; 52(1):121-6. PubMed ID: 1727372
[TBL] [Abstract][Full Text] [Related]
13. Comparative localization of glioma-reactive monoclonal antibodies in vivo in an athymic mouse human glioma xenograft model.
Wikstrand CJ; McLendon RE; Carrel S; Kemshead JT; Mach JP; Coakham HB; de Tribolet N; Bullard DE; Zalutsky MR; Bigner DD
J Neuroimmunol; 1987 May; 15(1):37-56. PubMed ID: 3571486
[TBL] [Abstract][Full Text] [Related]
14. Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model.
Hooijberg E; van den Berk PC; Sein JJ; Wijdenes J; Hart AA; de Boer RW; Melief CJ; Hekman A
Cancer Res; 1995 Feb; 55(4):840-6. PubMed ID: 7531616
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the colorectal carcinoma-associated antigen defined by monoclonal antibody D612.
Fernsten PD; Primus FJ; Greiner JW; Simpson JF; Schlom J
Cancer Res; 1991 Feb; 51(3):926-34. PubMed ID: 1988133
[TBL] [Abstract][Full Text] [Related]
16. [Monoclonal immunotherapy with human monoclonal antibody(CLN-IgG) in glioma patients].
Kubo O; Takakura K
Nihon Rinsho; 2002 Mar; 60(3):497-503. PubMed ID: 11904965
[TBL] [Abstract][Full Text] [Related]
17. Trial of targeting therapy against malignant glioma using monoclonal antibody.
Takahashi H; Teramoto A
J Nippon Med Sch; 2004 Feb; 71(1):2-3. PubMed ID: 15129587
[TBL] [Abstract][Full Text] [Related]
18. [Anti-TA226 human monoclonal antibody (ACA-11) against glioma].
Kokunai T
Nihon Rinsho; 2002 Jan; 60(1):100-6. PubMed ID: 11808318
[TBL] [Abstract][Full Text] [Related]
19. Unusually efficient tumor cell lysis by human effectors of antibody-dependent cellular cytotoxicity mediated by monoclonal antibodies.
Christiaansen JE; Sears DW
Cancer Res; 1984 Sep; 44(9):3712-8. PubMed ID: 6744288
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model.
Prins RM; Odesa SK; Liau LM
Cancer Res; 2003 Dec; 63(23):8487-91. PubMed ID: 14679014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
